Engflag

Meprotanum

Quick links to important sections

Meprotanum

Meprotanum_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Meprotanum

Property Description
Active ingredient Meprobamate
Form Tablet, Capsules (oral)
Pharmacological class Anxiolytic, Sedative/Hypnotic, Psycholeptic
General purpose Short-term relief of anxiety and tension
Origin Synthetic organic compound

Meprotanum: Definition and Pharmacological Classification

Meprotanum is a trade name for a medicinal product containing the active substance Meprobamate, which is classified pharmacologically as an anxiolytic and a sedative/hypnotic. This chemical belongs to the class of carbamate derivatives and falls under the broader group of psycholeptics, which are agents that suppress or dampen the Central Nervous System (CNS). Historically, Meprobamate was a pioneering compound, known under early brands such as Miltown or Equanil, and is clinically recognized for providing relief from emotional tension, anxiety, and restlessness. As a sedative used for anxiety disorders, the drug creates a calming effect by slowing down nervous system activity.

Composition, Chemical Origin, and Available Forms

The key component in Meprotanum is the compound Meprobamate, a substance resulting from synthetic organic chemistry rather than extraction from natural sources. This structure identifies it as a carbamate derivative. Meprotanum is a prescription-only product typically marketed as a single active ingredient in solid dosage forms, specifically as a tablet or in capsules, for oral administration. This allows for systemic absorption to address generalized tension, such as nervousness associated with temporary situational stress.

General Calming Purpose and Mechanism Summary

The general purpose of Meprotanum is to provide short-term relief from excessive tension by inducing a state of tranquilization and sedation. The high-level effect is achieved through general Central Nervous System (CNS) depression, meaning the drug reduces the overall excitability of the brain and spinal cord. This neuro-inhibition involves the substance modulating and enhancing the function of the brain's primary calming signal, GABA (gamma-aminobutyric acid), thereby strengthening the natural inhibitory tone across nerve cells. This effect contributes to both a generalized calming effect on the patient's emotional state and a reduction in associated muscle tension.

Regulatory References

  1. NIH defines Meprobamate as a sedative used for anxiety disorders

What side effects are possible with Meprotanum?

Possible Side Effects and Safety Information

The safety profile of Meprotanum (Meprobamate) is documented in regulatory sources based on its primary effect as a Central Nervous System (CNS) depressant. Adverse reactions are classified by the body systems affected and their frequency.

System-Organ Classes and Common Reactions

Adverse reactions primarily involve the CNS and Psychiatric systems, with the most common documented effects (incidence greater than 2%) including drowsiness, dizziness, and headache. Other reported effects on the nervous system include ataxia and generalized weakness. Gastrointestinal effects such as nausea and vomiting are also listed in official labeling.

Serious and Time-Related Safety Concerns

Rare but serious adverse reactions are documented, notably in the Hematologic system (e.g., aplastic anemia and agranulocytosis) and as severe hypersensitivity reactions (e.g., Stevens-Johnson syndrome and anaphylaxis). Time-related patterns exist, as allergic reactions typically occur within the first to fourth dose. Furthermore, physical dependence and withdrawal symptoms (including seizures) are associated with abrupt cessation following prolonged and excessive use.

Population-Specific Constraints

The official safety information specifies that caution in administration is required for older adults and those with impaired hepatic or renal function due to the potential for substance accumulation. The medication is also noted to have a potential to impair abilities necessary for performing coordinated tasks.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define Meprotanum (Meprobamate) overdose by its severe impact on the Central Nervous System (CNS) and cardiopulmonary function. Manifestations include severe drowsiness, stupor, ataxia, and slurred speech, progressing to coma.

Documented Severe Outcomes and Required Actions

Overdose carries a risk of life-threatening events, including shock, vasomotor collapse, and respiratory collapse, and has been reported to result in a fatal outcome. Blood concentrations exceeding 20 mg% are associated with a greater frequency of fatalities.

Immediate medical help must be sought at once if an overdose is suspected or if the person has collapsed, had a seizure, has trouble breathing, or can't be awakened. Government guidance advises calling emergency services or a poison control helpline.

No specific antidote is known for Meprobamate. Management focuses on symptomatic and supportive treatment, including necessary procedures like gastric emptying, administration of activated charcoal, and potential use of hemodialysis in severe cases. Regulatory guidelines require the careful monitoring of vital signs and urinary output during hospital observation. The effects of an acute overdose are additive when combined with alcohol or other CNS depressants.

Therapeutic Uses of Meprotanum

What Meprotanum Treats: Main Uses and Benefits

Meprotanum (Meprobamate) is commonly used to help with short-term, symptomatic assistance in conditions associated with heightened symptoms and tension. The product is generally indicated for the management of anxiety disorders or for the short-term easing of anxiety symptoms. Its therapeutic application may be part of symptomatic management in clinical settings that involve acute or unstable symptom patterns.

The medication supports patients by addressing symptom clusters that may become intense or disruptive, such as emotional tension, motor restlessness, and accompanying somatic tension. This helps maintain a sense of stability during periods where symptoms are more noticeable.

“It is applied in scenarios where additional management of discomfort is required due to temporary, pronounced tension.”

Quick Fact: Relief for Emotional Tension

The primary goal is offering symptomatic relief that may assist with maintaining a sense of stability during difficult episodes and supports general well-being during symptomatic phases. Meprotanum may be part of symptomatic management to help with sleep difficulties when symptoms are associated with acute worry or emotional stress.

Regulatory References

  1. NIH DailyMed Drug Label

Eligibility and Restrictions for Use

Who Can and Cannot Use Meprotanum?

The population eligibility for Meprotanum (Meprobamate) is strictly defined by regulatory documents, distinguishing between approved, conditional, and contraindicated groups.

Populations Contraindicated (Must Not Use)

  • Acute Intermittent Porphyria: Use is prohibited as the drug may precipitate acute attacks.
  • Hypersensitivity: Individuals with a history of allergic or idiosyncratic reactions to Meprobamate or related carbamate compounds must not use this medicine.

Age- and Condition-Based Restrictions

Population Group Regulatory Status
Adults Use is established for short-term relief of anxiety.
Children under 6 years Use is not recommended; safety and effectiveness are not established.
Older Adults Use requires caution due to increased sensitivity.
Hepatic or Renal Impairment Caution is mandatory to prevent drug accumulation.
Pregnancy (First Trimester) Use should be avoided.
Breastfeeding Use is not recommended as the drug is excreted in milk.

Conditional use requiring careful supervision is also required for patients with a history of seizure disorders, depression, or substance abuse propensity.

What should I know about interactions with other medicines?

Meprotanum (meprobamate) can interact with a wide range of other medicines and products, primarily by increasing the risk of central nervous system (CNS) depression. This can lead to excessive drowsiness, dizziness, trouble concentrating, and impaired coordination, which may result in severe respiratory depression, coma, and even death.

Patients must inform their healthcare provider of all prescription and non-prescription drugs, herbal products, and dietary supplements they are taking. Particular caution is required with agents that also cause sedation.

Major and Moderate Interactions

The most significant interactions involve other CNS depressants. Combining Meprotanum with these substances can dangerously enhance sedative effects. These include, but are not limited to:

  • Alcohol: Consumption of alcoholic beverages is strongly discouraged, as it significantly increases the risk of side effects like drowsiness and impaired motor function.
  • Benzodiazepines (e.g., alprazolam, diazepam, lorazepam).
  • Opioid analgesics and cough suppressants (e.g., hydrocodone, morphine, codeine).
  • Other sedatives, tranquilizers, and hypnotics (sleeping pills).
  • Antihistamines that cause drowsiness (e.g., diphenhydramine).
  • Tricyclic antidepressants (e.g., amitriptyline).
  • Muscle relaxants (e.g., carisoprodol).
  • Certain antiepileptics (e.g., barbiturates like phenobarbital).

If co-administration is necessary, dose adjustments and close monitoring by a healthcare professional are required to mitigate the increased risk of adverse effects.

Mechanism of Action

Meprotanum exerts its effects by modulating activity within the central nervous system (CNS), primarily through two key mechanistic domains.

GABAA Receptor Modulation

Meprotanum acts as a positive allosteric modulator on the GABA A receptor complex, a primary site of action for GABA-mediated inhibitory signaling. This engagement enhances the inhibitory effects of the neurotransmitter gamma-aminobutyric acid (GABA), increasing the influx of chloride ions ( Cl^-) into neurons. This process of hyperpolarization reduces the excitability of nerve cells, resulting in decreased neuronal excitability within the CNS.

Subcortical and Spinal Pathway Modulation

The drug engages mechanisms that influence polysynaptic reflexes within the spinal cord and subcortical regions. By inhibiting signal transmission through these neural pathways, Meprotanum results in reduced propagation of signal activity. This modification of signaling sequences can influence muscle tone and contributes to influencing feedback regulation within targeted neural circuits, a process that modulates systemic signal transduction.

Dosage and Administration Information

How to Use Meprotanum (Meprobamate): Official Administration Guidelines

This section outlines the administration and dosing instructions for Meprotanum (Meprobamate).

Official Administration Scope

Field Instruction
Route of Administration Oral.
Official Dosage Forms Immediate-release tablets, typically available in 200 mg and 400 mg strengths.
Standard Adult Dose 1200 mg to 1600 mg total per day.
Frequency The total daily dose is typically administered in three or four divided doses (e.g., every 6 to 8 hours) to ensure consistent drug levels.

Population-Specific Dosing and Procedures

  • Pediatric Use: Meprobamate is generally not recommended for children under 6 years of age. For children aged 6 to 12 years, the recommended total daily dose is 200 mg to 600 mg, administered in two or three divided doses.

  • Elderly and Debilitated Patients: A lower initial dose is required. Dosage selection should be cautious, typically starting at the low end of the adult dosing range to account for potential decreases in organ function, such as renal or hepatic impairment.

  • Duration and Discontinuation: Meprobamate is intended for short-term use. Following prolonged or excessive use, the medicine must not be stopped abruptly. To prevent withdrawal symptoms, the dosage must be reduced gradually over a period of one or two weeks under professional guidance.

Resulting Procedural Structure

The official protocol requires the patient to take the prescribed tablet dose orally, ensuring the total daily dose is appropriately divided and spaced throughout the day. Critically, the procedural instructions require a gradual tapering of the dose when ending therapy after long-term use, explicitly overriding the common instruction to simply stop taking the drug when finished.

Recent Clinical Evidence

Meprotanum: Recent Clinical Evidence

Meprotanum (also known as meprobamate) is a carbamate derivative anxiolytic, one of the first widely marketed tranquilizers. Clinical research in modern medicine primarily focuses on its established profile, efficacy limits, and safety compared to newer agents.

Efficacy and Use

The primary licensed indication for meprobamate in certain jurisdictions remains the short-term relief of anxiety symptoms or management of anxiety disorders. Historically, it was also used for insomnia and muscle relaxation. However, its use has significantly declined due to the development of benzodiazepines, which are often preferred due to their wider therapeutic index and more favorable safety profile.

  • Anxiety: Clinical studies from the mid-20th century suggested its benefit in alleviating symptoms of anxiety. However, the effectiveness of meprobamate as a selective anti-anxiety agent, separate from its sedative properties, has been questioned in later evaluations. The effectiveness beyond four months of use has not been thoroughly assessed in long-term studies.

Safety Profile and Regulatory Status

Recent regulatory reviews have focused heavily on the drug's safety risks. The European Medicines Agency (EMA) recommended the withdrawal of all marketing authorizations for oral meprobamate-containing medicines in the European Union. This recommendation was based on the conclusion that the benefits did not outweigh the risks, particularly concerning the potential for serious adverse effects.

Concerns highlighted in the review include:

Risk Factor Detail
Narrow Therapeutic Index Small difference between therapeutic dose and toxic dose, increasing the risk of serious or fatal accidental overdose.
Dependence Potential Risk of physical and psychological dependence, with severe withdrawal symptoms, including seizures and delirium, upon abrupt discontinuation.
CNS Depression Increased risk of profound sedation, confusion, and loss of consciousness, especially in older adults.

In the United States, meprobamate is classified as a Schedule IV controlled substance due to its potential for abuse and dependency. It is generally reserved for patients who have not responded to alternative treatments.

Frequently Asked Questions (FAQ)

Common questions about Meprotanum (FAQ)

Q: How long does Meprotanum take to start working after I take a dose?

Official information regarding Meprotanum, which contains the active substance meprobamate, indicates that the substance has a relatively long elimination half-life of approximately 10 hours. This suggests that its therapeutic effects are sustained. However, the exact onset of action (the time it takes for an initial effect to be noticed) can vary and is best discussed with a qualified professional.

Q: I missed a dose of Meprotanum, what should I do?

Regulatory guidance suggests skipping the missed dose entirely if it is forgotten. Patients are typically directed to then take the next scheduled dose at the usual time. It is generally advised not to take a double dose to compensate for the missed one, as this can increase the risk of side effects.

Q: What happens if I accidentally take too much Meprotanum?

Taking too much Meprotanum (an overdose) can be extremely serious and may lead to profound sedation, deep coma, and severe respiratory depression. Official safety warnings highlight that there is a narrow therapeutic index. Emergency medical help should be sought immediately if an overdose is suspected to ensure proper management.

Q: Can I take Meprotanum while driving?

Meprotanum is a Central Nervous System (CNS) depressant. Its official label cautions that common side effects, such as drowsiness and dizziness, can impair mental alertness and physical coordination. Official labels caution against driving, operating machinery, or performing other hazardous activities until an individual knows how Meprotanum affects them.

Q: How long can I take Meprotanum before I have to stop?

Meprotanum is used for the short-term relief of anxiety symptoms, according to the official product information. Research has not thoroughly assessed its effectiveness for use beyond a period of four months. Extended use is associated with a risk of developing physical and psychological dependence.

Q: Is there a maximum daily dose that I should never exceed?

The dosage of Meprotanum prescribed by a healthcare provider should not be exceeded. This caution is critical because official safety documents note there is a relatively small margin of safety between the effective dose and a dose that could cause serious toxicity. It is important to adhere strictly to the dosing schedule provided by a professional.

Q: What is the half-life of Meprotanum?

According to official pharmacokinetic data, the active ingredient in Meprotanum, meprobamate, has a terminal elimination half-life of approximately 10 hours. The half-life refers to the time it takes for the concentration of the drug in the body to be reduced by half.

How should Meprotanum be stored and disposed of?

Official Storage and Disposal Requirements

Storage and disposal instructions for Meprotanum (Meprobamate) are strictly defined by regulatory labeling to ensure product stability and safety. The medication must be kept at Controlled Room Temperature (20 to 25 C), with mandatory protection from both moisture and light. It is prohibited to store the product in conditions where it could freeze or be exposed to excessive heat.

Storage Requirement Rule
Packaging Keep in a tightly closed, light-resistant container.
Child Safety Keep out of the reach of children.

For disposal, unused or expired Meprotanum should be discarded using an official drug take-back program or the specific FDA household trash method. The medicine must not be flushed down a toilet or poured down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Meprotanum found in:

A-Z Index: